Systemic Sclerosis Market

Market Overview:

The 7 major systemic sclerosis markets reached a value of US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 6.07% during 2024-2034.

The systemic sclerosis market has been comprehensively analyzed in IMARC's new report titled "Systemic Sclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Systemic sclerosis, also referred to as scleroderma, is a rare autoimmune condition that affects the skin, blood vessels, and internal organs in the body. It is characterized by the production of excessive amounts of collagen, a fibrous protein that generally provides support and structure to the skin and other tissues. The most common symptom is the thickening and hardening of the skin, which can be either in localized or diffuse forms. In addition to skin changes, many people experience Raynaud's phenomenon, a condition in which the fingers and toes turn white or blue in response to cold or stress. Various other indications may include joint pain and stiffness, muscle weakness, fatigue, difficulty swallowing, heartburn, diarrhea, shortness of breath, coughing, high blood pressure in the lungs, etc. The diagnosis of systemic sclerosis is based on a combination of clinical features, laboratory tests, and imaging procedures. Numerous imaging studies, such as chest X-rays, echocardiograms, pulmonary function tests, etc., may also be used to assess the extent of organ involvement. In some cases, a skin biopsy or other tissue sample may be taken to confirm the diagnosis.

The increasing cases of endothelial cell dysfunction, which lead to abnormalities in blood vessel structure and function, are primarily driving the systemic sclerosis market. In addition to this, the rising prevalence of several associated risk factors, including exposure to silica, viral infections, genetic predisposition, etc., is also bolstering the market growth. Furthermore, the widespread adoption of calcium channel blockers, such as nifedipine and diltiazem, to manage Raynaud's phenomenon, a common symptom of systemic sclerosis that causes narrowing of blood vessels in the hands and feet, leading to coldness, numbness, and pain, is acting as another significant growth-inducing factor. Apart from this, the escalating demand for nailfold capillaroscopy, a non-invasive diagnostic technique, since it can distinguish systemic sclerosis from other connective tissue disorders and monitor disease progression effectively, is further creating a positive outlook for the market. Moreover, the inflating utilization of prostacyclin analogs, including epoprostenol, treprostinil, iloprost, etc., for managing pulmonary arterial hypertension by dilating blood vessels and reducing blood pressure is also augmenting the market growth. Additionally, the ongoing advancements in genomics and proteomics are enabling a better understanding of the underlying molecular mechanisms of the disease, which is further leading to the development of new treatment strategies. This, in turn, is expected to drive the systemic sclerosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the systemic sclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for systemic sclerosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the systemic sclerosis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the systemic sclerosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the systemic sclerosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current systemic sclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the systemic sclerosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the systemic sclerosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the systemic sclerosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of systemic sclerosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of systemic sclerosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of systemic sclerosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with systemic sclerosis across the seven major markets?
• What is the size of the systemic sclerosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of systemic sclerosis?
• What will be the growth rate of patients across the seven major markets?
   

Systemic Sclerosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for systemic sclerosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the systemic sclerosis market?
• What are the key regulatory events related to the systemic sclerosis market?
• What is the structure of clinical trial landscape by status related to the systemic sclerosis market?
• What is the structure of clinical trial landscape by phase related to the systemic sclerosis market?
• What is the structure of clinical trial landscape by route of administration related to the systemic sclerosis market?